Tata Steel achieved its best-ever quarterly crude steel production in Q3, with local production jumping 12% both annually and sequentially to 6.34 million tons. According to the latest company update, deliveries surged 14% YoY and 9% QoQ, primarily driven by strong sales in the domestic market. This represents a significant improvement from earlier reported figures and demonstrates the company's operational excellence. IRB Infrastructure maintained strong momentum with December gross toll collection rising 12% YoY to ₹754 crore, slightly higher than previously reported ₹753.8 crore. Meanwhile, NCL Industries recorded 5% YoY growth each in Q3 cement production and dispatches, with cement production reaching 6,94,854 MT in Q3 FY26 and dispatches at 6,93,229 MT, up 5% YoY.
Infosys partnered with Cognition to scale AI software engineer 'Devin' across global enterprises, marking a significant expansion in the company's artificial intelligence capabilities and positioning it at the forefront of AI-led value creation. Gland Pharma received US FDA approval for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC) for treating allergic conjunctivitis. The product is therapeutically equivalent to the reference listed drug Pataday Once Daily Relief, 0.7%, of Alcon Laboratories Inc. However, Cipla clarified that Pharmathen is the supply partner for Lanreotide Injection and is evaluating the impact of USFDA inspection, which could affect future operations. Beezaasan Explotech completed the export of its products to a foreign country with a total shipment value of approximately ₹2.3 crore, reflecting growing international presence.
HUDCO signed an MoU with the Chhattisgarh government for ₹1 lakh crore financial assistance over five years for housing and infrastructure projects, marking one of the largest infrastructure financing agreements announced recently. Angel One's board will meet on January 15 to consider a stock split, with the company reporting that December equity market share rose 62 bps, while Q3 market share increased 34 bps YoY. Balaji Amines became eligible for an industrial promotion subsidy of ₹258 crore for its Solapur unit expansion, providing significant financial support for the company's growth plans. Additionally, Kalpataru Projects received approval to sell 100% stake in Vindhyachal Expressway at an enterprise value of ₹775 crore, representing a major asset monetization move.
SG Finserve received RBI registration to undertake factoring business, expanding its financial services portfolio. ACS Technologies secured a work order worth ₹3,62,39,341 from Mahindra Defence Systems for supply, installation, testing, commissioning, and integration contract for security and communication systems. Midwest received a Quarry Lease Work Order from the Department of Mines & Geology, Andhra Pradesh for quarrying operations over 21.012 Hectares for a 30-year period commencing from January 6, 2026 to January 5, 2056. In market activity, LG Electronics will see 2% equity exit anchor lock-in, making these shares available for secondary market trading.
Panacea Biotec completed enrollment for the Phase-III Dengiall clinical trial with 10,335 study participants. According to the company, it will continue to monitor each participant for a period of two years post administration of the Investigational Medicinal Product (vaccine or Placebo) to examine the efficacy and immunogenicity of the vaccine. This milestone represents a significant step forward in the company's vaccine development program and positions the company closer to potential regulatory approval for its dengue vaccine candidate.
